Danaher Corporation
DHR
$194.98
-0.61%
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services, primarily focusing on scientific instruments and consumables in the life sciences and diagnostics industries. As a diversified science and technology leader, Danaher distinguishes itself through its Danaher Business System (DBS) and a portfolio of premier brands, positioning it as a market leader in diagnostics and life sciences tools. The current investor narrative centers on the company's post-Veralto spin-off transformation, with attention on its recent Masimo acquisition, organic growth recovery in bioprocessing, and margin expansion potential, though near-term headwinds from shipment delays and a 36% peak-to-trough decline have sparked debate about whether the stock is a value opportunity or facing structural challenges.…
DHR
Danaher Corporation
$194.98
Related headlines
Investment Opinion: Should I buy DHR Today?
Rating: Hold. Danaher is a high-quality company with a strong business model, but the current risk/reward is balanced given the expensive trailing valuation and uncertain near-term growth. The analyst consensus is 'strong_buy' with an average target of $227.61, implying 18.9% upside, but the low target of $195 suggests limited margin of safety.
Supporting Evidence: The forward P/E of 20.7x is reasonable and in line with peers, but the trailing P/E of 45.2x indicates that current earnings are depressed. Revenue growth of 3.66% YoY is modest, and the gross margin of 60.9% is healthy but not expanding. Free cash flow of $5.3B is strong, providing a 3.3% FCF yield. The PEG ratio of -9.26 is a red flag, signaling that the stock is not cheap on a growth-adjusted basis. Compared to the industry average P/E of ~25x, DHR's forward multiple is fair, but the trailing multiple is expensive.
Risks & Conditions: The biggest risks are a slower-than-expected bioprocessing recovery, Masimo integration issues, and multiple compression if earnings disappoint. This Hold would upgrade to Buy if the forward P/E compresses below 18x or if revenue growth accelerates above 10% YoY. It would downgrade to Sell if the stock breaks below $160 (52-week low) or if analyst downgrades accelerate. Overall, DHR appears fairly valued on forward earnings but overvalued on trailing earnings, making it a hold for now.
Sign up to view all
DHR 12-Month Price Forecast
Danaher's outlook is balanced. The forward P/E is reasonable, but the trailing P/E and negative PEG ratio highlight near-term earnings challenges. The strong buy consensus and high recurring revenue provide support, but the stock's underperformance and shipment delays warrant caution. The base case of a gradual recovery to $228 is most likely, but the bull and bear cases have meaningful probabilities. The stance is neutral given the conflicting signals: attractive forward valuation versus weak momentum. An upgrade to bullish would require clear evidence of accelerating revenue growth, while a downgrade to bearish would follow a break below $160.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $227.96 and implied upside of +16.9% versus the current price.
Average Target
$227.96
0 analysts
Implied Upside
+16.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$195 - $310
Analyst target range
Danaher is covered by 23 analysts, with a consensus recommendation of 'strong_buy' (mean rating 1.5 on a 1-5 scale). The average target price is $227.61, implying approximately 18.9% upside from the current price of $191.50. The distribution leans heavily bullish, with no sell ratings and only a few neutral ratings, reflecting broad optimism about the company's long-term prospects despite near-term headwinds. The target range spans from a low of $195.00 to a high of $310.00, indicating significant uncertainty. The high target of $310 assumes a robust recovery in bioprocessing, successful integration of Masimo, and multiple expansion, while the low target of $195 suggests only modest upside and prices in continued sluggish growth or margin compression. Recent ratings actions show a mix: Citigroup downgraded from Buy to Neutral in May 2026, while others like Evercore, HSBC, and UBS maintain positive stances, indicating some divergence in near-term views but overall conviction in the long-term story.
Drowning in data?
Find the real signal!
Bulls vs Bears: DHR Investment Factors
Danaher presents a classic value-versus-value-trap debate. The bull case rests on a strong buy consensus, reasonable forward P/E of 20.7x, high recurring revenue (84.5%), and robust free cash flow ($5.3B). The bear case highlights an expensive trailing P/E of 45.2x, negative PEG ratio, slowing revenue growth (3.66% YoY), and significant underperformance versus the market. The single most important tension is whether the expected earnings recovery materializes in the next 12 months: if bioprocessing demand rebounds and Masimo accretes, the forward multiple justifies the stock; if growth disappoints, the trailing multiple suggests further downside. Currently, the evidence slightly favors the bull case given the strong analyst consensus and reasonable forward valuation, but the risk of continued sluggishness is real.
Bullish
- Strong Buy Consensus with 18.9% Upside: 23 analysts rate DHR a 'strong_buy' with a mean rating of 1.5/5 and an average target of $227.61, implying 18.9% upside from $191.50. The high target of $310 suggests potential for 62% gains if bioprocessing recovers and Masimo integration succeeds.
- Forward P/E of 20.7x Is Reasonable: The forward P/E of 20.67x is in line with the medical diagnostics industry average of ~25x, suggesting the stock is not overvalued on expected earnings. This multiple is also well below DHR's 5-year trailing P/E range of 19x-64x, offering a margin of safety.
- Recurring Revenue Provides Stability: 84.5% of Q1 2026 revenue ($5.031B of $5.951B) is recurring, providing a predictable base. This high proportion of consumables and services revenue reduces earnings volatility and supports margin expansion.
- Strong Free Cash Flow Generation: TTM free cash flow is $5.291B, representing a robust 22.2% FCF yield on the current market cap of $161.9B. This cash generation supports debt reduction, acquisitions, and dividend growth.
Bearish
- Trailing P/E of 45.2x Is Expensive: The trailing P/E of 45.15x is nearly double the industry average of ~25x, indicating the market is pricing in aggressive earnings growth that may not materialize. If earnings disappoint, multiple compression could lead to significant downside.
- Negative PEG Ratio Signals Overvaluation: The PEG ratio of -9.26 is negative due to expected earnings decline, suggesting the stock is not cheap on a growth-adjusted basis. This implies that current earnings are depressed and any recovery may be slower than anticipated.
- Revenue Growth Deceleration: Q1 2026 revenue grew only 3.66% YoY, down from 6.5% in Q4 2025 and 7.4% in Q1 2025. The bioprocessing and diagnostics segments face headwinds, and the 12% weekly drop in July 2026 due to shipment delays underscores fragility.
- Stock Down 36% from Peak, Underperforming S&P 500: DHR is down 36% from its 52-week high of $242.80 and has a 1-year relative strength of -22.05% vs. the S&P 500. The stock's 1-year price change of -5.58% contrasts with the S&P 500's +16.47%, indicating persistent weakness.
DHR Technical Analysis
Danaher's 1-year price change of -5.58% masks a significant intra-year decline, with the stock currently trading at $191.50, which is 78.9% of its 52-week range (low $160.93, high $242.80). This positioning near the lower end of the range suggests the stock is in a corrective phase, having fallen from its highs, and may be viewed as a value opportunity if fundamentals support a recovery, though it also risks further downside if negative catalysts persist. The 52-week low of $160.93 provides a critical support level, while the high of $242.80 represents key resistance; a break above resistance would signal a trend reversal, while a breakdown below support could accelerate selling. With a beta of 0.823, Danaher is less volatile than the broader market, meaning its moves are relatively muted, which can be attractive for risk-averse investors but may also indicate less upside in a rally.
Beta
0.82
0.82x market volatility
Max Drawdown
-33.1%
Largest decline past year
52-Week Range
$161-$243
Price range past year
Annual Return
-1.1%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | +0.7% | +0.2% |
| 3m | +11.3% | +3.7% |
| 6m | -10.9% | +8.0% |
| 1y | -1.1% | +18.2% |
| ytd | -15.4% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory shows modest growth, with Q1 2026 revenue of $5.951 billion, up 3.66% year-over-year from $5.741 billion in Q1 2025. However, the multi-quarter trend reveals deceleration: Q4 2025 revenue was $6.838 billion, down from $6.538 billion in Q4 2024, and Q2 2025 revenue of $5.936 billion was essentially flat versus $5.743 billion in Q2 2024. The recurring revenue segment of $5.031 billion (84.5% of total) provides stability, but nonrecurring revenue of $0.92 billion highlights lumpiness in capital equipment sales. The growth deceleration, particularly in the bioprocessing and diagnostics segments, raises questions about end-market demand and the pace of recovery in life sciences spending.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+3.7%
YoY Comparison
Gross Margin
60.3%
Latest Quarter
Free Cash Flow
$5.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Since net income is positive ($1.029 billion in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E stands at 45.15x, while the forward P/E is 20.67x, implying the market expects significant earnings growth in the coming year. The wide gap between trailing and forward multiples suggests that current earnings are depressed and a sharp recovery is anticipated, which could be optimistic if growth disappoints. Compared to the industry average P/E (not provided, but typically ~25x for medical diagnostics), Danaher's trailing P/E of 45.15x appears expensive, but the forward P/E of 20.67x is more in line with peers. The PEG ratio of -9.26 is negative due to negative earnings growth expectations, indicating that the stock is not cheap on a growth-adjusted basis. Historically, Danaher's trailing P/E has ranged from ~19x to ~64x over the past five years; the current 45.15x is above the midpoint, suggesting the market is pricing in above-average growth expectations, which leaves little room for error.
PE
45.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Danaher's trailing P/E of 45.2x is elevated relative to the industry average of ~25x, leaving the stock vulnerable to multiple compression if earnings growth disappoints. The company's net income of $1.029B in Q1 2026 was down from $1.197B in Q4 2025, indicating earnings volatility. While the debt-to-equity ratio of 0.35 is manageable, the recent Masimo acquisition adds integration risk and potential goodwill impairment. The negative PEG ratio of -9.26 suggests that current earnings are depressed and the market expects a sharp recovery, which may not occur if bioprocessing headwinds persist. Additionally, the 12% weekly drop in July 2026 due to shipment delays highlights operational fragility in the biotech segment.
Market & Competitive Risks: DHR's beta of 0.823 indicates lower market correlation, but the stock has still underperformed the S&P 500 by 22% over the past year. The medical diagnostics industry faces pricing pressure and competition from peers like Thermo Fisher and Agilent. Regulatory risks include FDA approvals and healthcare policy changes. The recent downgrade by Citigroup from Buy to Neutral in May 2026 signals growing caution among some analysts. The stock's 36% decline from its 52-week high suggests a loss of investor confidence, and the low analyst target of $195 implies limited upside if the recovery stalls.
Worst-Case Scenario: If bioprocessing demand fails to recover, Masimo integration proves costly, and earnings continue to decline, DHR could retest its 52-week low of $160.93. This represents a 16% downside from the current price of $191.50. In a severe recession, the stock could fall further to the historical max drawdown of -33.11%, implying a price of ~$128. Given the stock's volatility and the negative relative strength, an investor could lose up to 35% in a prolonged downturn.
FAQ
The key risks are: 1) Financial: The trailing P/E of 45.2x leaves the stock vulnerable to multiple compression if earnings disappoint; net income declined from $1.197B in Q4 2025 to $1.029B in Q1 2026. 2) Operational: The 12% weekly drop in July 2026 due to shipment delays highlights execution risk in the biotech segment. 3) Competitive: The life sciences tools market is competitive, with players like Thermo Fisher and Agilent; pricing pressure could compress margins. 4) Macro: With a beta of 0.823, DHR is less volatile than the market, but a recession could delay the bioprocessing recovery. The most severe risk is a prolonged downturn that pushes the stock to the 52-week low of $160.93, a 16% decline from current levels.
The 12-month forecast is mixed. The base case (50% probability) sees the stock reaching the analyst average target of $227.61, driven by gradual revenue recovery and margin stability. The bull case (30% probability) targets $220-$310, assuming strong bioprocessing demand and successful Masimo integration. The bear case (20% probability) targets $161-$195, with risks of continued shipment delays and earnings misses. The most likely scenario is the base case, which assumes revenue growth of 4-6% YoY and operating margins around 21%. The AI assessment is neutral, citing the reasonable forward P/E but negative PEG ratio and weak momentum. Investors should monitor quarterly earnings for signs of acceleration or further deterioration.
DHR appears fairly valued on forward earnings but overvalued on trailing earnings. The forward P/E of 20.7x is in line with the medical diagnostics industry average of ~25x, suggesting the market expects a significant earnings recovery. However, the trailing P/E of 45.2x is nearly double the industry average, indicating that current earnings are depressed. The PEG ratio of -9.26 is negative due to expected earnings decline, which is a warning sign. Historically, DHR's trailing P/E has ranged from 19x to 64x over the past five years; the current 45.2x is above the midpoint, implying the market is pricing in above-average growth. Compared to peers, DHR's forward P/E is reasonable, but the stock is not a bargain on a trailing basis.
DHR is a good buy for long-term investors willing to accept near-term uncertainty. The analyst consensus is 'strong_buy' with an average target of $227.61, implying 18.9% upside. The forward P/E of 20.7x is reasonable compared to the industry average of ~25x, and the company generates strong free cash flow of $5.3B. However, the trailing P/E of 45.2x and negative PEG ratio of -9.26 indicate that current earnings are depressed, and the stock has underperformed the market by 22% over the past year. The biggest downside risk is a break below the 52-week low of $160.93, which would represent a 16% loss. For risk-tolerant investors with a 3-5 year horizon, DHR offers a compelling risk/reward; for short-term traders, the stock may remain range-bound until growth accelerates.
DHR is better suited for long-term investment. The stock has a beta of 0.823, indicating lower volatility than the market, and a dividend yield of 0.54% with a payout ratio of 24.3%, providing modest income. The high recurring revenue (84.5%) and strong free cash flow ($5.3B) support a buy-and-hold strategy. Short-term trading is risky due to the stock's 36% decline from its 52-week high and negative relative strength of -22% over the past year. The recommended minimum holding period is 3-5 years to allow the bioprocessing recovery and Masimo integration to materialize. For short-term traders, the stock may remain range-bound between $160 and $200 until a clear catalyst emerges.